NCT05800366 2026-03-05
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
Dana-Farber Cancer Institute
Stichting Hemato-Oncologie voor Volwassenen Nederland
Institut Cancerologie de l'Ouest
Institute of Hematology & Blood Diseases Hospital, China
University Hospital Schleswig-Holstein
University Hospital Muenster
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
University of Birmingham